Nevertheless, the overall diagnostic performance of IGFBP-7 and TIMP-2 remains consistent across studies, underscoring their reliability as biomarkers for renal dysfunction in multiple myeloma [14]. This evidence concerns the gene TIMP2 and plasma cell myeloma.